Table 2 Haematologic toxicity

From: Randomised phase III trial of FEC120 vs EC-docetaxel in patients with high-risk node-positive primary breast cancer: final survival analysis of the ADEBAR study

 

EC-Doc

FEC120

 

n =684

n =674

Any haematologic event

Grade 1–2

98 (14.3)

89 (13.2)

Grade 3–4

562 (82.2)

567 (84.1)

Anaemia

Grade 1–2

540 (78.9)

517 (76.7)

Grade 3–4

19 (2.8)

105 (15.6)

Leukopaenia

Grade 1–2

137 (20.0)

93 (13.8)

Grade 3–4

491 (71.8)

542 (80.4)

Neutropaenia

Grade 1–2

82 (12.0)

87 (12.9)

Grade 3–4

406 (59.4)

420 (62.3)

Thrombocytopaenia

Grade 1–2

213 (31.1)

313 (46.4)

Grade 3–4

13 (1.9)

160 (23.7)

Infection

Grade 1–2

290 (42.4)

216 (32.0)

Grade 3–4

66 (9.6)

104 (15.4)

  1. Abbreviations: EC-Doc=epirubicin/cyclophosphamide followed by docetaxel; FEC=fluorouracil/epirubicin/cyclophosphamide.
Back to article page